Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background There is limited previous research examining the healthcare costs of neovascular age-related macular degeneration (NV-AMD), which constrains our understanding of the economic impact of this condition. With aging populations, this leading cause of rapid vision loss in Western countries is expected to become a pressing health predicament, requiring decision makers to evaluate alternative treatment strategies for AMD.Objective To document the economic burden of bilateral NV-AMD, the late stage of AMD, in elderly patients, from a societal perspective. STUDY DESIGN, SETTING AND PARTICIPANTS: A cross-sectional, observational study surveyed 401 patients with bilateral NV-AMD and 471 non-AMD subjects in Canada, France, Germany, Spain and the UK. Physicians' records and subjects' standardized telephone interviews were used to record medical resource utilization, assistance with daily living and social benefits. Annual bilateral NV-AMD-related socioeconomic costs were calculated in euro, year 2005 values.Main outcome measures Societal costs including direct vision-related medical costs (e.g. treatment of AMD and vision-related equipment), direct non-vision-related medical costs (e.g. medications) and direct non-medical-related costs (e.g. home healthcare and social services) were the main outcome measures.Results The demographic profile of NV-AMD patients was similar across countries; however, co-morbid condition profiles varied. NV-AMD patients reported substantial health-related problems and associated health resource utilization (HRU). In the previous 12 months, 12-22% of patients fell, and half of these patients required medical treatments. More than 20% (range 21-59%) of patients were prescribed vision-enhancing equipment. More than half of the patients (54-81%) were living with a spouse or family member and 19-41% reported receiving assistance for activities of daily living. The average annual societal cost per bilateral NV-AMD patient treated was estimated to be euro 7879 in Canada, euro 7349 in France, euro 12 445 in Germany, euro 5732 in Spain and euro 5300 in the UK, and direct vision-related medical costs accounted for 23-63% of the total cost. Half of the patients were diagnosed with bilateral NV-AMD for <1 year, with an average length of 5 months; there were no statistically significant differences in total annual costs per patient between these patients and those who were diagnosed with bilateral disease for > or =1 year. Estimated annual societal costs of bilateral NV-AMD patients in these countries ranged from euro 268 to euro 1311 million. Estimated annual societal costs of all NV-AMD patients in these countries ranged from euro 671 to euro 3278 million.Conclusions Bilateral NV-AMD imposes significant functional impairment on patients, leading to increased HRU and a high societal cost burden. Differences in national healthcare systems and NV-AMD treatment patterns were reflected in the wide variation of NV-AMD costs across the five surveyed countries. Even though the prevalence rates and per-patient costs varied by country, the societal costs of NV-AMD patients were substantial in each country. Earlier intervention with effective therapies is expected to reduce disease burden and disability associated with NV-AMD and, thus, decrease the overall societal cost.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nine studies [34, 37–43, 45] reported direct non-medical costs per patient per annum, ranging from $688 to $15,418 (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [41]
In the citing paper
“Often, direct non-medical costs increased in line with the severity of vision impairment [37, 41, 42, 45] and in certain instances exceeded direct medical costs in patients with more severe vision impairment [42, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [41]
In the citing paper
“These figures ranged from $1.44 billion (Spain) to $6.27 billion (Germany) annually, partly reflecting differences in geographic settings and population sizes.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [41]
In the citing paper
“The most frequent resources accounted for within direct non-medical costs were formal care [34, 38–43, 45] and assistive technologies [34, 37–39, 41–43, 45], followed by transportation [34, 37–39, 42, 45] and subsidies [40–43] (Table 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [41]
In the citing paper
“While annual direct non-medical costs were uniformly lower than direct medical costs in three studies [34, 39, 40] reporting both types of costs, they were higher in other cases [37, 41–43, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [41]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Self-citationPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959
The epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
Fall-related factors and risk of hip fracture: the EPIDOS prospective study
Dargent-Molina, P., Favier, F., Grandjean, H., Baudoin, C., Schott, A., Hausherr, E., Meunier, P., & Bréart, G. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01440-7 · Cited by 901
Visual Impairment and Falls in Older Adults: The Blue Mountains Eye Study
BOptom, R. Q. I., Cumming, R. G., Mitchell, P., & Attebo, K. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb01014.x · Cited by 734
Prevalence of Age-Related Maculopathy in Older Europeans: The European Eye Study (EUREYE)
Augood, C. A. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.4.529 · Cited by 390
Epidemiology of Age-Related Macular Degeneration
Klein, R. (2005) · Macular Degeneration · doi:10.1007/3-540-26977-0_5 · Cited by 283
Cited by
Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature Review
Prokofyeva, E., & Zrenner, E. (2012) · Ophthalmic Research · doi:10.1159/000329603 · Cited by 212
Cabral de Guimaraes, T. A., Daich Varela, M., Georgiou, M., & Michaelides, M. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318452 · Cited by 186
Early and intermediate age-related macular degeneration: update and clinical review
Garcia-Layana, A., Cabrera-López, F., García-Arumí, J., Arias-Barquet, L., & Ruiz-Moreno, J. M. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s142685 · Cited by 178
“highly incapacitating in multiple physical, social, and emotional areas of patients as well as is leading to increased health resource utilization and high societal cost burden.(2)”
The economics of vision impairment and its leading causes: A systematic review
Marques, A. P., Ramke, J., Cairns, J., Butt, T., Zhang, J. H., Jones, I., Jovic, M., Nandakumar, A., Faal, H., Taylor, H., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101354 · Cited by 137
Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States
Smith, A. F., & Waycaster, C. R. (2009) · BMC Ophthalmology · doi:10.1186/1471-2415-9-13 · Cited by 135
Metadata
- Authors
- Cruess, A. F., Zlateva, G., Xu, X., Soubrane, G., Pauleikhoff, D., Lotery, A., Mones, J., Buggage, R., Schaefer, C., Knight, T., & Goss, T. F.
- Affiliations
- Dalhousie University (CA)
- Pfizer (United States) (US)
- Hôpital Intercommunal de Créteil (FR)
- St. Franziskus Hospital (DE)
- University of Southampton (GB)
- Corresponding author
- Cruess, Alan F
- Venue
- PharmacoEconomics
- Published
- 2008
- Volume
- 26
- Issue
- 1
- Pages
- 57-73
- ISSN
- 1170-7690 (ISSN-L)
- OpenAlex
- W2090658196
- Cited by
- 126
- References
- 21
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 8 · 2021: 8 · 2020: 3 · 2019: 19 · 2018: 9 · 2017: 6 · 2016: 4 · 2015: 11 · 2014: 7 · 2013: 3 · 2012: 9
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PharmacoEconomics (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- neovascular age-related macular degeneration, economic burden, social costs, health care costs, activities of daily living, falls, social services, comorbidities, cross-national comparison, elderly patients, vision loss, treatment costs, patient-reported outcomes, quality of life, health resource utilization
- MeSH terms
- Aged, Aged, 80 and over, Canada, Cross-Sectional Studies, Cross-Cultural Comparison, Europe, Female, Health Resources, Humans, Macular Degeneration, Male, Middle Aged, Prospective Studies, Quality of Life, Surveys and Questionnaires, Visual Acuity, Comorbidity, Case-Control Studies, Health Care Costs, Cost of Illness, Sickness Impact Profile, Choroidal Neovascularization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study. https://app.cochat.ai/papers/10.2165/00019053-200826010-00006
- The paper
- Cruess, A. F., Zlateva, G., Xu, X., Soubrane, G., Pauleikhoff, D., Lotery, A., Mones, J., Buggage, R., Schaefer, C., Knight, T., & Goss, T. F. (2008). Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study. PharmacoEconomics. https://doi.org/10.2165/00019053-200826010-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.